Adipocytokines and breast cancer risk

Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.
Chinese medical journal (Impact Factor: 1.02). 10/2007; 120(18):1592-6.
Source: PubMed

ABSTRACT Many researches suggested that obesity increased the risk of breast cancer, but the mechanism was currently unknown. Adipocytokines might mediate the relationship. Our study was aimed to investigate the relationship between serum levels of resistin, adiponectin and leptin and the onset, invasion and metastasis of breast cancer.
Blood samples were collected from 80 newly diagnosed, histologically confirmed breast cancer patients and 50 age-matched healthy controls. Serum levels of resistin, adiponectin and leptin were determined by enzyme-linked immunosorbent assays (ELISA); fasting blood glucose (FBG), lipids, body mass index (BMI), and waist circumference (WC) were assayed simultaneously.
Serum levels of adiponectin ((8.60 +/- 2.92) mg/L vs (10.37 +/- 2.81) mg/L, P = 0.001) and HDL-c were significantly decreased in breast cancer patients in comparison to controls. Serum levels of resistin ((26.35 +/- 5.36) microg/L vs (23.32 +/- 4.75) microg/L, P = 0.000), leptin ((1.35 +/- 0.42) microg/L vs (1.06 +/- 0.39) microg/L, P = 0.003), FBG and triglyceride (TG) in breast cancer patients were increased in contrast to controls, respectively. However, we did not find the significant difference of the serum levels of resistin, adiponectin and leptin between premenopausal breast cancer patients and healthy controls (P = 0.091, 0.109 and 0.084, respectively). The serum levels of resistin, adiponectin and leptin were significantly different between patients with lymph node metastasis (LNM) and those without LNM (P = 0.001, 0.000 and 0.006, respectively). The stepwise regression analysis indicated that the tumor size had the close correlation with leptin (R(2) = 0.414, P = 0.000) and FBG (R(2) = 0.602, P = 0.000). Logistic regression analysis showed that reduced serum levels of adiponectin (OR: 0.805; 95% CI: 0.704 - 0.921; P = 0.001), HDL (OR: 0.087; 95% CI: 0.011 - 0.691, P = 0.021), elevated leptin (OR: 2.235; 95% CI: 1.898 - 4.526; P = 0.004) and resistin (OR: 1.335; 95% CI: 1.114 - 2.354; P = 0.012) increased the risk for breast cancer; Reduced serum levels of adiponectin (OR: 0.742; 95% CI: 0.504 - 0.921; P = 0.003) and elevated leptin (OR: 2.134; 95% CI: 1.725 - 3.921; P = 0.001) were associated with lymph node metastasis of breast cancer.
The decreased serum adiponectin levels and increased serum resistin and leptin levels are risk factors of breast cancer. The low serum adiponectin levels and high serum leptin levels are independent risk factors for metastasis of cancer. The association between obesity and breast cancer risk might be explained by adipocytokines.

1 Follower
  • Source
    • "Among the known adipocye-derived hormones, Adiponectin is unique from others [12] [14]. While excess adipose tissue in obese subjects increase production of most of adipokines such as leptin, obese subjects have a lower serum level of adiponectin in comparison to their lean counterparts, moreover weigh loss can increase serum level of adiponectin [3] [15]. Many in vitro studies revealed the anti-tumoral effects of this adipocytokine such as its anti-angiogenic, pro apoptotic, anti inflammatory and anti prolifrative activities that propose it as a potent tumor suppressor gene [16] [17]. "
    Journal of Cancer Therapy 02/2012; 3(1):115-121. DOI:10.4236/jct.2012.31015
  • Source
    • "Despite the well-recognized relationship between obesity and estrogenic activity, it is evident that this cannot fully explain the association between adiposity and breast cancer risk [14]. Indeed, the adipose tissue is increasingly viewed as not only a fat-storing tissue but also an endocrine organ secreting various adipocytokines [15]. Subsequently, both experimental and epidemiological data suggest the possible role of adipocytokines in the regulation of carcinogenesis as another link between obesity and breast cancer [1]. "
    Clinical Biochemistry 09/2011; 44(13). DOI:10.1016/j.clinbiochem.2011.08.159 · 2.28 Impact Factor
  • Source
    • "In breast cancer patients, no significant difference was found in HGFand age. Similar findings are found by Sheen-Chen et al., (2005) and others (Yamashita et al., 1994; Wei-Kai et al., 2007 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocyte growth factor (HGF) also known as scatter factor (SF) and its receptor c-met play important roles in mammary differentiation and have been implicated in mammary carcinogenesis. Objective: Estimation of the plasma level of HGF in females with benign breast lumps or breast carcinomas and correlating levels with important prognostic parameters. Subjects: Sixty eight adult premenopausal females were divided into control group of fifteen healthy volunteers and fifty-three patients subdivided into fifteen with benign breast lumps and thirty-eight with breast carcinomas. A thorough clinical examination, plain chest x-rays, ultrasonography of the abdomen and pelvis, pre- operative fine needle aspiration cytology, estimation of fasting serum glucose, urea, creatinine and uric acid levels, alanine aminotransferase activities, C-reactive protein, HGF level and histopathological examination of the breast masses were performed. Significant increase in HGF levels was found in patients with benign breast lumps and in breast cancer patients when each was compared to controls and when cancer patients were compared to the benign breast lumps group. The serum level of HGF is an independent prognostic indicator for breast cancer.
    Asian Pacific journal of cancer prevention: APJCP 01/2010; 11(4):893-6. · 2.51 Impact Factor
Show more


Available from